3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
9
Phase 2
7
Phase 1/2
5
Phase 3
2
Phase 2/3
2
Phase EARLY_PHASE1
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
26
Thoracic
6
Gastrointestinal
6
Head & Neck
5
Other hematologic neoplasm
3
Genitourinary
3
Dermatologic
3
Plasma cell
2
Myeloid
2
Endocrine
2
CNS
2
Breast
2
Sarcoma
1
Lymphoid
1
Conditions
Neuroendocrine Tumors
7
Thyroid Carcinoma, Anaplastic
3
Thyroid Cancer, Papillary
3
Neoplasms
3
Multiple Endocrine Neoplasia Type 1
3
Thyroid Neoplasms
2
Somatostatinoma
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Laryngeal Neoplasms
2
Hematologic Neoplasms
2
Glioma
2
Gastroenteropancreatic Neuroendocrine Tumors
2
Erdheim-Chester Disease
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Adrenal Gland Neoplasms
2
Adenoma, Islet Cell
2
Vipoma
1
Thyroid cancer, Hurthle cell
1
Pituitary Neoplasms
1
Pheochromocytoma
1
Parathyroid Neoplasms
1
Paraganglioma
1
Muscle Weakness
1
Motor Activity
1
Melanoma
1
Interventions
trametinib
1
dabrafenib
1
cobimetinib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Ovarian Neoplasms
×
Endocrine
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled